Current immunotherapies
are being utilized in patients with weakened immunometabolism

This has compromised treatment efficacy
with an unwanted
increase in toxicity

Metabolic dysfunction
is currently not being addressed at all

Because of this metabolic dysfunction, the immune system remains activated and attacks “self” tissue